These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24615630)
1. α-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Boyd K; Hilas O Ann Pharmacother; 2014 Jun; 48(6):711-22. PubMed ID: 24615630 [TBL] [Abstract][Full Text] [Related]
2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Djavan B; Marberger M Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649 [TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers. Belayneh M; Korownyk C Can Fam Physician; 2016 Sep; 62(9):e523. PubMed ID: 27629686 [No Abstract] [Full Text] [Related]
5. Tamsulosin for benign prostatic hyperplasia. Wilt TJ; Mac Donald R; Rutks I Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426 [TBL] [Abstract][Full Text] [Related]
6. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Lowe FC Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685 [TBL] [Abstract][Full Text] [Related]
7. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Miller MS Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068 [TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510 [TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. Na YJ; Guo YL; Gu FL J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165 [TBL] [Abstract][Full Text] [Related]
10. [Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results]. Oelke M; Höfner K; Berges RR; Jonas U Urologe A; 2002 Sep; 41(5):425-41. PubMed ID: 12426859 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. Yan H; Zong H; Cui Y; Li N; Zhang Y J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088 [TBL] [Abstract][Full Text] [Related]
12. α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different? Roehrborn CG; Cruz F; Fusco F Adv Ther; 2017 Jan; 33(12):2110-2121. PubMed ID: 27752927 [TBL] [Abstract][Full Text] [Related]
13. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Garimella PS; Fink HA; Macdonald R; Wilt TJ Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408 [TBL] [Abstract][Full Text] [Related]
14. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. Rossi C; Kortmann BB; Sonke GS; Floratos DL; Kiemeney LA; Wijkstra H; de la ROSETTE JJ J Urol; 2001 Jan; 165(1):38-41. PubMed ID: 11125359 [TBL] [Abstract][Full Text] [Related]
15. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Schneider MP; Tornic J; Sýkora R; Abo Youssef N; Mordasini L; Krhut J; Chartier-Kastler E; Davies M; Gajewski J; Schurch B; Bachmann LM; Kessler TM Neurourol Urodyn; 2019 Aug; 38(6):1482-1491. PubMed ID: 31099113 [TBL] [Abstract][Full Text] [Related]
16. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs. La Torre A; Giupponi G; Duffy D; Conca A; Cai T; Scardigli A Pharmacopsychiatry; 2016 Jan; 49(1):3-13. PubMed ID: 26569417 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P; Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148 [TBL] [Abstract][Full Text] [Related]
18. Medical therapy for benign prostatic hyperplasia: a review of the literature. Clifford GM; Farmer RD Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436 [TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
20. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Schilit S; Benzeroual KE Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]